U.S. pharma giant copyright scrapped two experimental weight loss drugs final 12 months—a at the time-day by day pill, lotiglipron, on account of elevated liver enzymes along with a twice-day by day capsule, danuglipron, due to solid Unwanted side effects—but CEO Albert Bourla has said the company is determined to “Participate in and acquire�